Antiangiogenic chemotherapeutic agents

Cancer and Metastasis Reviews

Volumn 19, Issue 1-2, 2000, Pages 67-73

  Schirner, M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; Chemotherapy; Dose scheduling; Drug treatment

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL KILLING; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034534249     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026500431505     Document Type: Review

References (35)

1. The biological action and therapeutic application of beta-chloroethyl amines and sulfides
2. Experimental evaluation of potential anticancer drugs. XII. On the criteria and kinetics associated with curability of experimental leukemia
3. A Gompertzian model of human breast cancer growth
4. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models
5. Tumor angiogenesis: Therapeutic implications
6. What is the evidence that tumors are angiogenesis dependent?
7. Tumor angiogenesis - New drugs on the block
8. Antiangiogenesis is produced by nontoxic doses of vinblastine
9. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
10. Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in a transplanted mouse mammary tumor
11. Endothelial cell proliferation in tumors and normal tissue: Continuous labelling studies
12. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
13. Endothelial cell proliferation as a novel approach to targeting tumor therapy
14. Endothelial injury caused by antineoplastic agents
15. Vinca alkaloids: Anti-vascular effects in a murine tumor
16. Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury
17. High dose continuous infusion of bleomycin in mice: A new model for drug-induced pulmonary fibrosis
18. Anti-vascular approaches to solid tumor therapy: Evaluation of vinblastin and flavone acid
19. Inhibition of growth of colon 38 adenocarcinoma by vinblastin and cholchicin: Evidence for a vascular mechanism
20. The microtuble-affecting drug paclitaxel has antiangiogenic activity
21. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitor 2-methoxyestradiol and taxol
22. Paclitaxel (taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
23. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
24. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay
25. Inhibition of angiogenesis by anthracyclines and titanocene dichloride
26. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
27. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptpthecin, topotecan, and CPT-11 studied in the mouse cornea model
28. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air say assay in mice
29. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
30. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
31. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A-4 phosphate
32. Blood flow influences vascular growth during tumour angiogenesis
33. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
34. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamyl-fumagillol-TNP.470) and cytotoxic agents in mice
35. Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization